Fontana Limited

What it is

Fontana Limited buys and sells pharmaceutical and related products in Jamaica, with a range spanning baby goods, beauty, groceries, electronics, gifts, and stationery — far wider than a conventional pharmacy. For over 56 years it has been a trusted name on the island, adding services such as WhatsApp prescription, home delivery, and in-store business centres alongside its pharmacy counters.

After growing revenue 17 per cent to JMD 9.52 billion in its June-2025 financial year, Fontana expanded its physical footprint from seven to 11 locations through the acquisition of Monarch Pharmacy assets. The company made the transition from a family-operated entity to a structured public company when it listed on the Jamaica Junior Stock Exchange in December 2018.

Who owns it

Fontana Limited operates as a subsidiary of Burbank Holdings Limited, the Chang family’s private holding vehicle. Burbank sold 16.6 million ordinary shares during the 2025 financial year, trimming its stake to 961.3 million shares, or 76.94 per cent of the company.

Wayfair Holdings Limited bought 8.65 million of those shares from Burbank on 24 March 2025, at JMD 9 per share. The remaining roughly 23 per cent is the public free float on the Jamaica Stock Exchange.

Exact ownership percentages for minority shareholders beyond Burbank are not disclosed in available sources.

Who runs it

The company’s name was inspired by a nearby fountain and the birth of Bobby Chang’s sixth child, Anne — he merged “fountain” and “Anne” to coin “Fontana.” Anne Chang is today the CEO of the establishment. Kevin O’Brien Chang is Chairman; on returning from Canada in 1989 he oversaw the growth of the original Mandeville location and later spearheaded the opening of the Montego Bay branch in 1994.

Raymond (Ray) Therrien is Chief Operating Officer and has been a Director of the company for many years. The CFO title is not disclosed in available sources.

Founder Bobby Chang — known within the company as “Shinque Chang” — passed away on 26 December 2025; he had resigned from the board in February 2025 and his passing did not affect the board’s composition or operations.

The money, in plain words

In its fiscal year 2025, Fontana’s revenue reached JMD 9.52 billion — a rise of 17 per cent compared with the prior year’s JMD 8.13 billion. At JMD 591.56 million (US$3.77 million), the net profit works out to about JMD 6.2 cents kept for every JMD 1 of sales — a net margin of 6.2%, respectable for a pharmacy-retail hybrid (our calculation).

Return on equity is 20.5% — for every dollar shareholders have put into the business, Fontana earns back about 20 cents per year, a strong result for the sector. The company carries JMD 1.6 billion in cash against JMD 2.54 billion in debt, leaving a net debt position of JMD 943.5 million (US$6.0 million, our calculation) — modest, but a shift from earlier years that reflects the bond issued to fund the Monarch deal.

The most recent dividend was JMD 0.25 per share, with an ex-date of 28 May 2026 and a payment date of 12 June 2026, producing a yield of roughly 3.9%. With a payout ratio of around 68 per cent, the dividend is covered by earnings, though cash flows are currently stretched by capital spending on the new stores.

What it is doing now

In early 2025 Fontana spent more than JMD 672 million to acquire the Monarch Pharmacy business, raising JMD 650 million from a bond to fund the purchase; Monarch had been owned by Gerk Limited for 35 years. Monarch operates four locations — three in St Andrew and one in Portmore — bringing Fontana’s total store count from seven to 11.

The company also launched its “Ora by Fontana” luxury beauty concept stores at its Fairview and Waterloo branches in April 2025, adding Fenty Beauty by Rihanna to its product range. A MyJPS Care Hub — a partnership with Jamaica’s main electricity provider — opened at the Portmore location and Fontana is in talks to roll the concept out to other sites.

What to watch

• Monarch integration costs. The 13 per cent rise in operating expenses during Q3 FY2025 was largely driven by additional staffing for the phased opening of new Monarch locations. Until those stores reach full productivity, margins will remain under pressure.
• Debt paydown versus expansion. Management is actively weighing whether to pay down the acquisition debt with cash on hand or reserve that capital for further expansion over the next two to five years.
• Controlling shareholder sales. Burbank trimmed its stake during FY2025; further sales could widen the free float and improve trading liquidity, but signal a shift in family commitment worth monitoring.
• Founder transition. The death of founder Shinque (Bobby) Chang in December 2025 closes a founding chapter; how Anne Chang and Kevin O’Brien Chang steer the next expansion phase is the key management question.

This is news, not investment advice.